n-stent restenosis (ISR) remains the major limitation to long-term positive outcomes after percutaneous coronary intervention (PCI). 1,2 Pathological analyses indicate that the formation of neointimal tissues in the implanted stent is a major cause of ISR, which is characterized by an inflammatory reaction at the site of balloon-induced vascular injury, the migration and proliferation of vascular smooth muscle cells, and the synthesis of excess matrix. Despite the well-defined nature of the lesion, the pathogenic mechanisms leading to accelerated neointimal hyperplasia remain largely undefined. Multiple studies have examined potential risk factors for ISR and have reported that conventional coronary risk factors such as hypertension, hyperlipidemia, smoking habits, and a family history of coronary artery disease (CAD) are not associated with an increased risk of ISR. 2, 3 This may be attributable to differences in the pathology of post-stenting restenosis and atheromatous plaque in CAD. 4 In contrast, type 2 diabetes mellitus (T2DM) has been reported as a strong risk factor for ISR, possibly because Circulation Journal Vol.71, November 2007 patients with diabetes display a tendency toward exaggerated intimal hyperplasia inside the stent. 3, 5, 6 Studies in animal models have suggested that the inflammatory and proliferative responses to balloon-induced vascular injury are enhanced in diabetes. 7, 8 The metabolic alterations that occur as a result of hyperglycemia or hyperinsulinemia can accelerate many of the pathophysiologic processes that lead to restenosis. Diabetes results in endothelial dysfunction and accelerated platelet deposition, both of which increase the propensity to thrombosis. Several growth factors known to promote the restenosis process are overexpressed in the presence of hyperglycemia. Advanced glycosylation promotes inflammatory cell recruitment and smooth muscle cell proliferation. 9 Although the accumulating evidence from in vitro and in vivo studies demonstrate the increased risk of ISR in diabetes, the precise mechanism underlying the clinical observations remains uncertain.
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Oxidative modification of low-density lipoprotein (LDL) has been demonstrated to play a central role in the initiation and acceleration of atherosclerosis. 10 Oxidized LDL exerts several proatherogenic effects, including direct cytotoxicity to endothelial cells, the promotion of increased synthesis and secretion of adhesion molecules, increased monocyte chemotaxis and adhesion, and enhanced foam cell formation in atherosclerotic lesions. 11, 12 It has been reported that oxidized LDL promotes vascular smooth muscle cell proliferation. 13, 14 Recently, immunoassays using monoclonal antibodies prepared against oxidized LDL demonstrated that human blood contains oxidized LDL and that higher levels were found in patients with CAD. 15 Serum level of
Increased Incidence of Coronary In-Stent Restenosis in Type 2 Diabetic Patients is Related to Elevated Serum Malondialdehyde-Modified
Low-Density Lipoprotein oxidized LDL was also increased in diabetic patients who developed vascular complications. 16 A high concentration of circulating oxidized LDL is considered as an independent and significant predictor for future cardiac events in T2DM patients with CAD. 17 Although the nature of the oxidized LDL in the serum of diabetic patients has not been defined, adverse effects of circulating oxidized LDL in diabetes have been strongly suggested. In the present study, we investigated the potential risk factors for ISR, especially in T2DM patients, and we disclose for the first time that an elevated serum level of malondialdehyde-modified LDL (MDA-LDL), a major oxidized LDL, relates to the increase in the incidence of ISR observed in diabetic patients.
Methods

Patient Population
A total of 131 patients (old myocardial infarction, 65; stable effort angina pectoris, 66) who underwent coronary stenting were enrolled in this study. Patients with acute myocardial infarction, unstable angina pectoris, chronic total occluded lesion, renal failure (serum creatinine >2 mg/dl), liver disorder, or malignancy were excluded. All patients were treated with 100 mg/day aspirin and 200 mg/day ticlopidine after stenting. Ticlopidine was given for 1 month after stenting, but aspirin was administered indefinitely. Subacute stent thrombosis did not occur in the enrolled patients. None of the patients in this study received drug-eluting stents, intracoronary brachytherapy, or any other type of investigational local drug therapy or investigational stent implantation.
Coronary Angiographic Evaluation
All patients who received intracoronary stent(s), underwent an angiographic follow-up examination 6 months after stenting. Coronary angiograms were obtained in multiple projections in identical views at baseline, immediately after stent placement, and at follow-up after 6 months, and were stored as digital images. Quantitative angiographic analysis was made by operators unaware of the clinical characteristics of the patients, using the automated edge detection system (CAAS II for Toshiba Infinix; Pie Medical imaging, The Netherlands). The length of the stenosis was estimated with electronic calipers and the contrast-filled catheter tips were used for calibration. The diameters of the proximal and distal reference segments were averaged by the system to yield the reference luminal diameter (RD). The percent diameter stenosis was calculated as the difference between the minimal luminal diameter (MLD) and RD. Binary ISR was defined as >50% diameter stenosis at follow-up.
Measurement of MDA-LDL
Venous blood sampling, including MDA-LDL, was performed in the fasting state upon admission for follow-up angiography. In some diabetic patients, MDA-LDL was measured just before and 30 min after treatment of ISR (ie, re-ballooning of restenosis site). We used an enzyme-linked immunosorbent assay for the detection of MDA-LDL, based on the principles previously reported by Kotani et al. 18 Venous blood samples were collected and the sera were separated within 4 h. Prior to storage at -20°C, the serum samples were mixed with a stabilizing reagent according to the procedure described by Kitano et al. 19 The samples were diluted 2,000-fold in a dilution buffer containing SDS. Duplicate 100-l aliquots of the diluted sample were then added to the wells of plates coated with monoclonal antibody against MDA-LDL (ML25; Daiich Pure Chemicals, Tokyo, Japan). ML25 has previously been shown to recognize MDA residues. After incubation for 2 h at room temperature, the plates were washed, and -galactosidase-conjugated monoclonal antibody against apoprotein B (AB16; Daiich Pure Chemicals) was added. It has been shown that the combination of positive immunoreactions with both ML25 and AB16 recognizes MDA-LDL. After an additional incubation for 1 h at room temperature, the plates were washed, and 100-l of 10 mmol/L o-nitrophenyl-galactopyranoside was added. The reaction was stopped after 2 h by adding 100-l of 0.2 mol/L sodium carbonate (pH 12). The absorbance at 405 nm and the reference absorbance at 650 nm were determined using a microplate reader (M-Vmax, Molecular Devices, CA). A prepared solution of MDA-LDL was used as a primary standard, in which 15% of the total amino groups were modified. We tentatively defined 1 unit/L MDA-LDL as the absorbance obtained with the primary standard at a concentration of 1 mg/L. A calibration curve was prepared using 500-to 8,000-fold dilutions of a reference serum, the secondary standard, and the amount of MDA-LDL in the samples was calculated from the curve. The reference sera were prepared from pooled sera from healthy volunteers. In the preliminary study, serum MDA-LDL level in the healthy volunteers was 58.8±17.9 U/L (n=86) (unpublished data).
Statistical Analysis
A simultaneous and a stepwise multiple regression analysis were used to evaluate the independent association of various risk factors with ISR. A comparison of the variables among 4 groups (Figs 1,3 ) was performed using 1-way analysis of variance with a post-hoc test (Fisher's PLSD). Linear regression analysis and Pearson correlation coefficients was used for comparisons between the glycohemoglobin and MDA-LDL concentrations (Fig 2) . Student's unpaired t-test was used for comparison of MDA-LDL level before and after PCI (Fig 4) . Statistical significance was defined as p<0.05.
Results
Clinical and laboratory characteristics of the enrolled patients are shown in Table 1 . Of 131 patients, 38 developed ISR within 6 months after stenting and 93 patients did not. A stepwise multiple regression analysis was used to evaluate the independent association of various risk factors with ISR. Sex difference (male gender), T2DM, and elevation of glycohemoglobin (HbA1c) were positive univariate factors, and medication of HMG-CoA reductase inhibitor (statin) was a negative univariate factor for ISR. However, T2DM was the only independent risk factor for ISR ( Table 1) .
The analysis shown in Table 1 clearly indicates that T2DM is a significant risk factor for ISR. In fact, the percentage ISR rate was 44.2% in diabetic patients (19/43 patients) compared with 21.6% in non-diabetic patients (19/88 patients). Thus, we investigated the diabetes-related risk factors that promote ISR. A stepwise multiple regression analysis was also used to evaluate the independent association of these variables with ISR in diabetic patients ( Table 2) . Male gender and elevated serum MDA-LDL concentration were positive univariate factors, and medication with HMG-CoA reductase inhibitor (statin) and the HDL-cholesterol concentration were negative univariate factors for ISR. However, only elevation of the serum MDA-LDL concentration was an independent risk factor for ISR (Table 2) . Fig 1 compares the average concentration of serum MDA-LDL in diabetic and non-diabetic patients with or without ISR. A significant elevation of serum MDA-LDL concentration was observed only in the diabetic patients who developed ISR. We examined whether the serum MDA-LDL level relates to the control of diabetes and it was positively correlated to HbA1c in diabetic patients (Fig 2) . Interestingly, this trend was not observed in non-diabetic patients. In contrast, the HbA1c level was not statistically different between the ISR and non-ISR groups of diabetic patients (Fig 3) . These results suggest the possibility that an elevated plasma glucose level does not directly promote ISR, but rather the metabolic abnormality caused by a high plasma glucose level increases serum MDA-LDL, which results in the increased rate of ISR. To exclude the possibility that an elevated serum MDA-LDL is simply derived from the restenosis site (ie, neointima in the stent), we investigated whether the serum MDA-LDL level is altered after treatment of ISR, but as shown in Fig 4, it was not significantly decreased after treatment (ie, mechanical crushing of the neointima with a PCI balloon). This result strongly suggests that an elevated level of serum MDA-LDL in diabetic patients is not merely a consequence of restenosis.
Discussion
T2DM is a serious risk factor for poor outcome after percutaneous transluminal coronary angioplasty. 21 Although coronary stents improve the acute results and decrease the rate of restenosis compared with balloon angioplasty, diabetes remains a key independent predictor of ISR. 5, 21, 22 After stenting of native coronary arteries, diabetic patients have significantly more restenosis of the lumen than nondiabetic patients, as determined by quantitative coronary angiographic analysis, regardless of the treatment modality for diabetes. 6 Serial intravascular ultrasound analysis has shown that accelerated intimal hyperplasia in the stented lesion is the main cause of the increased restenosis in diabetic patients. 23 In contrast, most risk factors for CAD are not associated with an increased risk of restenosis. 2, 3 In the present study, we found no significant correlation of the various risk factors for CAD to ISR, except for diabetes. Thus, our result is quite consistent with previous reports in which diabetes is a potent risk factor for restenosis after coronary stenting. 3, 5, 24 The mechanisms involved in the development of ISR in diabetic patients have been extensively investigated in animal models. The metabolic alterations caused by diabetic hyperglycemia or hyperinsulinemia are considered to be involved in many of the pathophysiologic processes leading to restenosis. Long-term hyperglycemia leads to the formation of advanced glycation endproducts (AGEs); the accumulation of AGEs and their receptors in the vessel wall has been implicated in the neointimal formation after vascular injury in diabetic rats. 25 Hyperinsulinemia rather than hyperglycemia may be of crucial importance in promoting the exaggerated neointimal hyperplasia after balloon injury. Hyperinsulinemia has been shown to induce cell proliferation through the activation of the Ras/MARK pathway in diabetic animals. 26 Park et al evaluated 2 different models of DM: streptozotocin (STZ)-treated Sprague-Dawley rats (type 1 DM) and obese Zucker rats (type 2 DM). Neointimal hyperplasia was assessed by computerized morphometry after carotid balloon injury. Whereas there was no difference in the neointimal area in the STZ-treated rats compared with the controls, the neointimal area was markedly increased in the obese Zucker rats, which suggested the possibility that insulin resistance is associated with a propensity for neointimal proliferation. 8 Although the data from animal studies have suggested several possible pathways that might underlie the exacerbation of ISR in diabetes, the precise mechanisms of ISR in clinical observations remain poorly defined.
Local and mechanical factors, such as implantation of multiple stents, longer stents, and small stent diameter, have been reported as independent predictors of ISR after coronary intervention. [1] [2] [3] 27 Kastrati et al reported that stent placement procedures yielding a final MLD of less than 3 mm increased the likelihood of restenosis by 50% and doubled the likelihood of target lesion revascularization. 1 The lesion length was also reported to be a significant correlate of lumen loss at 6-month angiographic follow-up. 28 However, factors related to the implanted stents did not seem to be the prime cause of ISR observed in the diabetic patients in the present study.
The present study showed for the first time that the markedly increased rate of post-stenting restenosis observed in diabetic patients is associated with an increased serum MDA-LDL concentration. This trend was not observed in the non-diabetic patients, suggesting the adverse effects of elevated serum MDA-LDL to ISR are peculiar to diabetic patients. MDA-modified LDL, one of the major oxidized LDL, has been known to play key roles in the progression of atherosclerosis. 29, 30 The serum level of MDA-LDL is increased in CAD patients, and is positively correlated with the thickness of the intima media in the carotid arteries. 31 Circulating MDA-LDL is distributed in serum fractions containing small, dense LDL 18 and the elevated circulating MDA-LDL is considered to be a potent risk factor for atherosclerosis. 32 On the other hand, the level of circulating MDA-LDL is reported to be elevated in patients with diabetes 33 and in STZ-induced diabetic rats. 34 The mechanisms underlying the increase in MDA-LDL in diabetes have not been fully clarified, although enhancement of lipoperoxidation and decreased glutathione levels are reportedly involved in the elevated level of MDA-LDL. 35 Interestingly, treatment with pravastatin, an HMG-CoA reductase inhibitor, can normalize elevated MDA-LDL levels without affecting the LDL-cholesterol level, suggesting that its effects might be attributable to decreased LDL oxidation. 34 The precise pathway between elevated serum MDA-LDL and increased ISR was not defined in this study. Oxidized LDL has been reported to exert direct cytotoxicity on endothelial cell, to promote synthesis and secretion of adhesion molecules, and to increase monocyte chemotaxis and adhesion. 11, 12 Oxidized LDL increases vascular smooth muscle cell proliferation 13, 14 and the mitogenic effect of oxidized LDL on vascular smooth muscle cells is mediated by the activation of the Ras/Raf/MEK/MAPK pathway. 36 The inflammatory and proliferative effects of oxidized LDL may be accountable for the enhancement of neointimal cell proliferation that leads to ISR in diabetic patients.
The source of the elevated serum MDA-LDL in the diabetic patients who developed restenosis was uncertain in this study; however, the observed increase in MDA-LDL did not seem to be derived from local restenosis site (ie, neointima in the stent). First, pathology of the restenosis site consists of proliferated neointima and lacks a lipid core of oxidized LDL that might be the source of circulating MDA-LDL. Second, increased serum MDA-LDL levels were not observed in non-diabetic patients, including those who developed ISR (Fig 1) . Finally, serum MDA-LDL levels were not altered after treatment of restenosis with balloon angioplasty to mechanically abrogate the neointima at the restenosis site (Fig 4) . Interestingly, serum MDA-LDL was positively correlated with HbA1c level in diabetic patients (Fig 2) , although HbA1c did not relate to ISR itself (Fig 3) . These results support the notion that the elevation of serum MDA-LDL is attributable to the metabolic abnormalities of T2DM and acts as a promoter of ISR in diabetic patients.
The present study clearly showed that an elevated level of serum MDA-LDL in diabetic patients relates to ISR. However, because measurement of MDA-LDL was performed during the follow-up period in this study, it is uncertain whether the MDA-LDL level at the time of PCI predicts future ISR. In this respect, diabetic patients tend to have no apparent angina symptoms, even when significant restenosis has occurred. Thus, measurement of serum MDA-LDL during follow-up period, seems to be useful as an indicator of the potential development of ISR in these less symptomatic diabetic patients.
In conclusion, an elevated serum MDA-LDL concentration appears to be a major adverse factor for ISR in diabetic patients. Further studies are necessary to investigate the upstream and downstream pathways leading to ISR associated with elevated MDA-LDL and to determine the origin of the increased serum MDA-LDL in diabetic patients.
